bluebird bio BLUE
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
bluebird bio (BLUE) Core Market Data and Business Metrics
Latest Closing Price
$5.03Price-Earnings Ratio
-0.20Total Outstanding Shares
9.79 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
455 Grand Union Boulevard, Somerville, MA, 02145
Historical Stock Splits
If you bought 20 shares of BLUE before December 13, 2024, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| December 13, 2024 | 1-for-20 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 228,737 Shares | 8.09 | 3/14/2025 | 1,850,979 Shares |
| 964,510 Shares | 2.07 | 2/28/2025 | 1,994,568 Shares |
| 223,116 Shares | 12.21 | 2/14/2025 | 2,724,761 Shares |
| 160,527 Shares | 15.75 | 1/31/2025 | 2,528,252 Shares |
| 216,724 Shares | 11.15 | 1/15/2025 | 2,416,860 Shares |
| 575,995 Shares | 4.19 | 12/31/2024 | 2,413,977 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-260.02 Million |
| Net Cash Flow From Investing Activities, Continuing | $3.90 Million |
| Net Cash Flow From Investing Activities | $3.90 Million |
| Net Cash Flow, Continuing | $-168.65 Million |
| Net Cash Flow From Financing Activities | $87.47 Million |
| Net Cash Flow From Financing Activities, Continuing | $87.47 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-240.72 Million |
| Cost Of Revenue | $89.38 Million |
| Income/Loss From Continuing Operations Before Tax | $-181.08 Million |
| Income/Loss From Continuing Operations After Tax | $-240.70 Million |
| Revenues | $83.81 Million |
| Benefits Costs and Expenses | $264.89 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-241.05 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-337,000 |
| Comprehensive Income/Loss Attributable To Parent | $-241.05 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-241.05 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $-31.53 Million |
| Other Current Liabilities | $272.71 Million |
| Intangible Assets | $9.55 Million |
| Noncurrent Assets | $305.56 Million |
| Accounts Payable | $34.32 Million |
| Other Non-current Assets | $296.02 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||